资讯

Vietnam Investment Review10 小时
Innovent Showcases Breakthrough Preclinical Data on Novel Antibodies at AACR 2025
IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...
Taiwan News11 小时
2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including ...
IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell ...